AVENUE SOLUTIONS

AVENUE SOLUTIONS filed a Q3 report for OMEROS CORPORATION on October 20, 2026, reporting $50,000 in lobbying income.

Lobbying for OMEROS CORPORATION · Biopharmaceutical company

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

Washington

Lobbying activity 1

Issues related to Pediatric Review Voucher (PRV); H.R. 10359, Priority for Pediatric Cures Act

Bills named in this filing 1

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.